Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc.

Varian provides software and machines for oncology, alongside patient data and care team solutions, focusing on Intelligent Cancer Care.

Varian

Perspective Therapeutics is a pharmaceutical company focused on developing therapies for treating cancer from the inside out. The company aims to create treatments that make a difference for cancer patients and the clinicians who treat them.

Perspective Therapeutics

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.

Our first human imaging with [203Pb]PSV359 suggests rapid uptake and sustained retention in multiple cancer types. PSV359 is a novel peptide developed by our in-house discovery team which targets Fibroblast Activation Protein-α (FAP).  

Imaging was performed by Dr. Ishita Sen’s group at Fortis Memorial Research Institute - India.

Further information will be available in upcoming presentations and publications.
 
https://lnkd.in/ePh7Z6Zh

#nuclearmedicine #radiopharma #oncology

We're #hiring a new Discovery Lab Organic Chemist in Coralville, Iowa. Apply today or share this post with your network.

Perspective Therapeutics is pleased to announce the appointment of Steve Keefe, MD, MSCE, as Senior Vice President, Clinical Development. 

Dr. Keefe joins us from Merck, where he led global clinical development in gynecologic cancers. His team at Merck was instrumental in advancing groundbreaking therapies, including pembrolizumab, olaparib, and lenvatinib, as well as pioneering combination strategies with earlier-stage compounds.

He received his MD from the University of Chicago and completed a fellowship in Medical Oncology at Penn Medicine. His journey in oncology continued as a clinical investigator at the University of Pennsylvania, where he served on the faculty of the School of Medicine.

We are confident that Dr. Keefe's broad experience in oncology drug development further strengthens our capabilities in bringing our novel radiopharmaceutical medicines all the way to patients and their families. Join us in welcoming Dr. Keefe to the team!

#Radiopharmaceuticals #Oncology

We're excited to be attending the 3rd Annual Targeted Radiopharmaceuticals Summit this week!
Our CBO, Amos Hedt, will be participating in a panel discussion on Wednesday, July 31, and a seminar on Thursday, August 1, focused on the current state and the future of #radiopharmaceuticals.

Learn more at: https://bit.ly/3WrwrcX

Perspective’s CB7-Adma Pre-targeting Platform!

Host -> CB7-conjugated antibody
Guest -> Adma-modified radionuclide
Lag time post Host administration -> Flexible (determined by peak Host tumor uptake and clearance) 

Our best-in-class platform aims to transform a wide range of existing molecules and targets into “radio-ADCs” to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. Revolutionizing cancer treatment with a new breakthrough approach.

https://lnkd.in/eBr3zAT6

We're #hiring a new Executive Administrative Assistant in Coralville, Iowa. Apply today or share this post with your network.

Metric
Company Name	Perspective Therapeutics, Inc.	Varian
Symbol	CATX
MSH ID	COM:PERSPECTIVETHERAPEUTICS	COM:VARIAN
Market	STOCKS	PRIVATE
Sector		Healthcare & Health Services
Industry		Medical Technology
Country	US	US
Stage
Employee Count	119
Website	perspectivetherapeutics.com	varian.com
LinkedIn	perspective-therapeutics
Founders

Metric
Market Cap	251.43M
Enterprise Value
Monthly Web Traffic	1.10K	235.65K
Web Traffic Growth	-0.81	0.90
Valuation
Raised Capital

Metric
Revenue	7.10M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.63M
EBITDA	-14.84M
Operating Income	-15.18M
Net Income	-14.67M
EPS	-0.10
Diluted EPS	-0.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.11
Operating Profit Margin	-5.13
EBITDA Margin	-2.09
Net Profit Margin	-3.40
Return on Equity	-0.20
Return on Assets	-0.19
Return on Capital Employed	-0.21

COM:PERSPECTIVETHERAPEUTICS

Perspective Therapeutics

Last Close

3.00

22/11 21:00

Market Cap

192.62M

Beta: -

Volume Today

9.18M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-9.88
P/B Ratio	2.40
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	264.05
EV Multiple	-18.79

Metric
Days Sales Outstanding	89.32
Days Payables Outstanding	224.22
Days Inventory Outstanding	112.49
Operating Cycle	297.82
Cash Conversion Cycle	-76.17
Asset Turnover	0.06

Metric
Operating Cash Flow	-36.91M
Free Cash Flow	-37.98M
Cash Flow to Debt	-5.50
Operating Cash Flow/Sales	-3.94
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	9.24M
Accounts Receivable	-426K
Inventory
Goodwill	24.06M
Debt to Capitalization	0.03
Debt to Assets	0.03
Current Ratio	2.67
Quick Ratio	2.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.49
R&D to Revenue	2.24
SG&A to Revenue	2.68